IRVINE, CA, and HERSTAL, BELGIUM, September 3, 2015 – 7:00 AM CET – MDxHealth SA (Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, announced today that it received the following notification of significant shareholdings, in accordance with the Belgian Act of May 2, 2007 on the disclosure of significant shareholdings in issuers of which the shares are admitted to trading on a regulated market.

Shareholdings after actively crossing the transparency threshold:

Alychlo NV informed MDxHealth on August 31, 2015 that, as of August 28, 2015, its participation in MDxHealth has exceeded the threshold of 3% of the outstanding shares. Alychlo NV which is controlled by Mr. Marc Coucke, owns 1.459.938 shares, i.e. 3,32 % of the outstanding shares of MDxHealth. For further information, reference is made to the information published on MDxHealth’s website (

About MDxHealth
MDxHealth is a multinational healthcare company that provides actionable epigenetic information to personalize the diagnosis and treatment of cancer. The company’s tests are based on proprietary gene methylation (epigenetic) technology and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. For more information visit and follow us on Twitter at:

For more information:


Dr. Jan Groen, CEO
US: +1 949 812 6979
BE: +32 4 364 20 70  


Mike Sinclair (PR)
Halsin Partners
UK: +44 20 7318 2955
Cell: +44 7968 022075  


Amber Fennell (IR)
UK: +44 20 3709 5701
Cell: + 44 7739658783

This press release may contain forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company’s control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.

NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.